These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28267723)

  • 1. Celgene eyes 'inverse vaccines' in Anokion and Delinia deals.
    Sheridan C
    Nat Biotechnol; 2017 Mar; 35(3):189-190. PubMed ID: 28267723
    [No Abstract]   [Full Text] [Related]  

  • 2. Deal watch: Celgene bets big on Scripps-originated autoimmunity candidate.
    Cully M
    Nat Rev Drug Discov; 2015 Sep; 14(9):595. PubMed ID: 26294266
    [No Abstract]   [Full Text] [Related]  

  • 3. Tipping the balance towards tolerance: the basis for therapeutic immune modulation by gold?
    Carey JB; Carey MA; Allshire A; van Pelt FN
    Autoimmunity; 2005 Sep; 38(6):393-7. PubMed ID: 16278143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines and vaccine adjuvants as biological response modifiers.
    Speil C; Rzepka R
    Infect Dis Clin North Am; 2011 Dec; 25(4):755-72. PubMed ID: 22054754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropeptides as therapeutic approach to autoimmune diseases.
    Gonzalez-Rey E; Delgado-Maroto V; Souza Moreira L; Delgado M
    Curr Pharm Des; 2010; 16(28):3158-72. PubMed ID: 20687881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunomodulating therapy of rheumatoid arthritis].
    Balabanova RM; Barakat B
    Revmatologiia (Mosk); 1990; (3):38-44. PubMed ID: 2151541
    [No Abstract]   [Full Text] [Related]  

  • 7. Footrace to clinic heats up for T-cell nuclear receptor inhibitors.
    Sheridan C
    Nat Biotechnol; 2013 May; 31(5):370. PubMed ID: 23657373
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacologic developments for the therapeutic use of biological response modifiers].
    Schröder W; Bender HG
    Gynakologe; 1992 Aug; 25(4):258-67. PubMed ID: 1398255
    [No Abstract]   [Full Text] [Related]  

  • 9. Aspirin and immune system.
    Hussain M; Javeed A; Ashraf M; Zhao Y; Mukhtar MM; Rehman MU
    Int Immunopharmacol; 2012 Jan; 12(1):10-20. PubMed ID: 22172645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cyclosporin A in inflammatory rheumatic diseases].
    Gross WL; Rob PM
    Internist (Berl); 1996 Jan; 37(1):91-7. PubMed ID: 8837835
    [No Abstract]   [Full Text] [Related]  

  • 11. Rituximab in the treatment of autoimmune haematological disorders.
    Provan D; Newland AC; Amadori S; Stasi R
    Br J Haematol; 2008 Oct; 143(2):294; author reply 295. PubMed ID: 18752592
    [No Abstract]   [Full Text] [Related]  

  • 12. [Tolerance and safety of drug arglabin].
    Tabriz NS; Skak KS; Mytaikhan ZhM; Kozhamuratov MT; Serikbaev NM
    Georgian Med News; 2014 Dec; (237):70-6. PubMed ID: 25617105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research in practice: the impact of interferon-α therapy on immune tolerance.
    Raker V; Steinbrink K
    J Dtsch Dermatol Ges; 2014 Apr; 12(4):315-9. PubMed ID: 24628847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biotherapies targeting T and B cells: from immune suppression to immune tolerance.
    Chatenoud L
    Curr Opin Pharmacol; 2015 Aug; 23():92-7. PubMed ID: 26099946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunomodulation therapy for autoimmune diseases. New hope for patients with autoimmune diseases].
    Szegedi G
    Orv Hetil; 2005 Apr; 146(14):635-43. PubMed ID: 15889537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy with intravenous gammaglobulins in systemic inflammatory autoimmune diseases: new indications?].
    Sánchez-Ramón S; Valor L
    Med Clin (Barc); 2014 Aug; 143(3):130-3. PubMed ID: 24480286
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of the human genome on the discovery of immune-modulatory therapeutics.
    Manning AM
    Curr Opin Investig Drugs; 2006 May; 7(5):406-11. PubMed ID: 16729715
    [No Abstract]   [Full Text] [Related]  

  • 18. Evolution of nanomedicines for the treatment of autoimmune disease: From vehicles for drug delivery to inducers of bystander immunoregulation.
    Yang Y; Santamaria P
    Adv Drug Deliv Rev; 2021 Sep; 176():113898. PubMed ID: 34314782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cell depletion: on the rise.
    Hinze CH; Grom AA
    J Pediatr; 2007 Apr; 150(4):335-7. PubMed ID: 17382106
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravenous immunogloblins: myth and reality.
    Tellier Z
    Isr Med Assoc J; 2005 Dec; 7(12):762-7. PubMed ID: 16382695
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.